Skip to main content
. 2016 Nov 1;7(48):79187–79202. doi: 10.18632/oncotarget.13007

Figure 7. NKG2D expression correlates to survival of leukemia mice after in vivo IL pre-activation and re-stimulation.

Figure 7

(A) Rag1KO B6 (CD45.2+) mice were divided into two groups: one group of mice received IgG1 as control (IL, □), and another group of mice received anti-NKG2D antibody for neutralization (IL+NKG2D mAb, ■). Both groups of mice received pre-activation (4.5 μg/mouse IL-12, 5.5 μg/mouse IL-15, and 22 ng/mouse IL-18) and re-stimulation (5 μg/mouse IL-12 and 8 μg/mouse IL-15) prior to treatment with the antibodies and 1×104 Notch1-T-ALL cells post NKG2D neutralization. Kaplan-Meier analysis was performed to assess survival of mice (median survival time: 75 days for the IgG1 control group and 59 days for the anti-NKG2D mAb group. Values indicate mean ± SD (n = 10 per group, p < 0.05). (B) In parallel, mRNA expression levels of IFNγ were determined by qRT-PCR, Values indicate mean ± SD (n = 10 per group).